A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults

To evaluate the efficacy of Tapinarof cream, 1% in subjects with atopic dermatitis (AD).

Principal Investigator(s)

Dr. Jonathan Silverberg MD, PHD, MPH

Request Information

First Name

Last Name

Email Address

Confirm email

Phone Number

Address

Address 2

City/Town

State/Province

ZIP/Postal Code

Comments / Questions

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.